NMRA Company Profile and Key Details

NASDAQ : NMRA

Neumora Therapeutics Common Stock

$2.33

0.03000001+1.30%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Neumora Therapeutics, Inc. Common Stock (NMRA) stock surged +1.30%, trading at $2.33 on NASDAQ, up from the previous close of $2.30. The stock opened at $2.32, fluctuating between $2.27 and $2.42 in the recent session.

Stock Snapshot

2.3

Prev. Close

425.66M

Market Cap

2.27

Day Low

-1.61

P/E Ratio

-1.45

EPS (TTM)

-2.78

Cash Flow per Share

2.32

Open

182.69M

Number of Shares

2.42

Day High

40.32%

Free Float in %

10.05

Book Value

1.71M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 06, 2026	2.32	2.42	2.27	2.33	1.7M
May 05, 2026	2.36	2.40	2.23	2.30	693.23K
May 04, 2026	2.44	2.48	2.29	2.31	1.23M
Apr 30, 2026	2.29	2.51	2.23	2.47	1.23M
Apr 29, 2026	2.24	2.37	2.20	2.25	1.14M
Apr 28, 2026	2.22	2.30	2.16	2.25	2.06M
Apr 27, 2026	2.25	2.31	2.18	2.22	952.96K
Apr 23, 2026	2.30	2.31	2.19	2.23	1.18M
Apr 22, 2026	2.42	2.46	2.26	2.31	1.57M
Apr 21, 2026	2.20	2.41	2.09	2.32	1.86M
Apr 20, 2026	2.12	2.32	2.07	2.19	1.96M
Apr 17, 2026	2.04	2.19	1.99	2.15	1.42M
Apr 16, 2026	2.07	2.07	1.96	2.00	668.1K
Apr 14, 2026	2.10	2.17	1.99	2.03	2.1M
Apr 13, 2026	2.03	2.21	2.02	2.06	917.48K
Apr 10, 2026	2.09	2.14	2.01	2.04	765.22K
Apr 09, 2026	2.16	2.16	2.05	2.08	849.57K
Apr 08, 2026	2.22	2.24	2.15	2.18	1.15M
Apr 07, 2026	2.11	2.19	2.04	2.13	1.3M
Apr 06, 2026	2.01	2.15	1.97	2.12	1.71M

Contact Details

Watertown, DE 02472

United States

https://www.neumoratx.com 857 760 0900

About Company

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Stock Peers

ARGX

12.85+1.62%

argenx SE$807.55 REGN

18.78+2.67%

Regeneron Pharmaceuticals, Inc.$721.05 UTHR

24.56+4.29%

United Therapeutics Corporation$596.76 MDGL

37.26+7.42%

Madrigal Pharmaceuticals, Inc.$539.73 VRTX

3.29+0.78%

Vertex Pharmaceuticals Incorporated$427.65 PRAX

4.77+1.43%

Praxis Precision Medicines, Inc.$338.07 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.89+0.63%

Alnylam Pharmaceuticals, Inc.$303.00 KRYS

4.42+1.55%

Krystal Biotech, Inc.$288.99 ASND

10.62+4.71%

Ascendis Pharma A/S$235.90

Company Overview

Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) closed at $2.33 USD, gaining $0.03 (1.30%) from the previous close of $2.30. The stock is currently mid-range between its 52-week high and low $0.61 and $3.65. With a market capitalization of about $425.66 million, Neumora Therapeutics, Inc. Common Stock is classified as a small-cap and shows higher-than-market volatility (beta ~3.05). Key stats such as the average daily volume over the past year has been around 1.43 million shares, in line with its 52-week average. Headquartered in Watertown, DE, Neumora Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daljit Singh Aurora, the company employs approximately 110 people and listed since September 15, 2023. Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 24.82%, SMA50 54.05%, SMA200 95.16%). The stock’s 14-day RSI is 75.45 (overbought), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.74% below its high and over 481.01% above its low. Average 10-day trading volume of 1.29 million shares is in line with the 3-month average of 1.43 million, indicating normal recent market interest.

Dividend & Fair Value

Neumora Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.11. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Neumora Therapeutics, Inc. Common Stock generated EPS of -$1.46 over the past year. Five-year average earnings growth is -586.93%. Wall Street analysts project EPS growth of 12.73% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 4 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.00. The high target offers 500.86% upside. The low target suggests 28.76% downside. The mean target is $8.38. This offers 259.66% upside. Neumora Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended March 16, 2026, missed forecasts by 2.94%. The prior quarter beat by 2.94%. Over the last six quarters, Apple has recorded several small beats. These include 18.42% in November 12, 2024.

Shareholding & Insider Activity

Neumora Therapeutics, Inc. Common Stock has 161.94 million shares outstanding. The public float is 86.06 million shares, elevated short interest at 12.20% of float. This equals 7.16 million shares. The short ratio is 3.47 days. Institutional investors hold 74.2% of the float. Insiders own 24.25%. BERNS PAUL L holds 7.40 million shares, ARCH Venture Partners X, LLC has 6.05 million shares and Burow Kristina has 6.05 million shares. Over the past six months, insider transactions show net selling. They sold 138.09 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Neumora Therapeutics Common Stock has not generated any revenue.
On valuation metrics, Neumora Therapeutics Common Stock trades at a P/E of -1.64, P/S of 0.00 and P/B of 3.74. The current ratio is 5.87 and quick ratio is 5.87. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -246.67 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -432.79.

Quarterly Financial Highlights

The company ended the quarter with $453.98M in cash and short-term investments, a total debt of $5.23M, and net debt of - $368.81M. Total assets were $496.20M, with equity of $469.08M. Financials further reflected weakness, with operating cash flow of - $163.28M, free cash flow of - $163.40M, and capital expenditures of - $117.00K.

Frequently Asked Questions

What is the current Neumora Therapeutics, Inc. Common Stock (NMRA) stock price?

Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) stock price is $2.33 in the last trading session. During the trading session, NMRA stock reached the peak price of $2.42 while $2.27 was the lowest point it dropped to. The percentage change in NMRA stock occurred in the recent session was 1.3% while the dollar amount for the price change in NMRA stock was $0.03.

NMRA's industry and sector of operation?

The NASDAQ listed NMRA is part of Biotechnology industry that operates in the broader Healthcare sector. Neumora Therapeutics, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NMRA?

No Data

How NMRA did perform over past 52-week?

NMRA's closing price is 281.34% higher than its 52-week low of $0.61 where as its distance from 52-week high of $3.65 is -36.16%.

How many employees does NMRA have?

Number of NMRA employees currently stands at 110.

Link for NMRA official website?

Official Website of NMRA is: https://www.neumoratx.com

How do I contact NMRA?

NMRA could be contacted at phone 857 760 0900 and can also be accessed through its website. NMRA operates from 490 Arsenal Way, Watertown, DE 02472, United States.

How many shares of NMRA are traded daily?

NMRA stock volume for the day was 1.71M shares. The average number of NMRA shares traded daily for last 3 months was 1.43M.

What is the market cap of NMRA currently?

The market value of NMRA currently stands at $425.66M with its latest stock price at $2.33 and 182.69M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

2.3

Prev. Close

425.66M

Market Cap

2.27

Day Low

-1.61

P/E Ratio

-1.45

EPS (TTM)

-2.78

Cash Flow per Share

2.32

Open

182.69M

Number of Shares

2.42

Day High

40.32%

Free Float in %

10.05

Book Value

1.71M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 06, 2026	2.32	2.42	2.27	2.33	1.7M
May 05, 2026	2.36	2.40	2.23	2.30	693.23K
May 04, 2026	2.44	2.48	2.29	2.31	1.23M
Apr 30, 2026	2.29	2.51	2.23	2.47	1.23M
Apr 29, 2026	2.24	2.37	2.20	2.25	1.14M
Apr 28, 2026	2.22	2.30	2.16	2.25	2.06M
Apr 27, 2026	2.25	2.31	2.18	2.22	952.96K
Apr 23, 2026	2.30	2.31	2.19	2.23	1.18M
Apr 22, 2026	2.42	2.46	2.26	2.31	1.57M
Apr 21, 2026	2.20	2.41	2.09	2.32	1.86M
Apr 20, 2026	2.12	2.32	2.07	2.19	1.96M
Apr 17, 2026	2.04	2.19	1.99	2.15	1.42M
Apr 16, 2026	2.07	2.07	1.96	2.00	668.1K
Apr 14, 2026	2.10	2.17	1.99	2.03	2.1M
Apr 13, 2026	2.03	2.21	2.02	2.06	917.48K
Apr 10, 2026	2.09	2.14	2.01	2.04	765.22K
Apr 09, 2026	2.16	2.16	2.05	2.08	849.57K
Apr 08, 2026	2.22	2.24	2.15	2.18	1.15M
Apr 07, 2026	2.11	2.19	2.04	2.13	1.3M
Apr 06, 2026	2.01	2.15	1.97	2.12	1.71M

Contact Details

Watertown, DE 02472

United States

https://www.neumoratx.com 857 760 0900

About Company

Stock Peers

ARGX

12.85+1.62%

argenx SE$807.55 REGN

18.78+2.67%

Regeneron Pharmaceuticals, Inc.$721.05 UTHR

24.56+4.29%

United Therapeutics Corporation$596.76 MDGL

37.26+7.42%

Madrigal Pharmaceuticals, Inc.$539.73 VRTX

3.29+0.78%

Vertex Pharmaceuticals Incorporated$427.65 PRAX

4.77+1.43%

Praxis Precision Medicines, Inc.$338.07 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.89+0.63%

Alnylam Pharmaceuticals, Inc.$303.00 KRYS

4.42+1.55%

Krystal Biotech, Inc.$288.99 ASND

10.62+4.71%

Ascendis Pharma A/S$235.90

Company Overview

Technical Performance

Valuation Metrics

Neumora Therapeutics, Inc. Common Stock trades at a P/E ratio of -1.64, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.74 trading at moderately above to book value. The P/FCF stands at -2.1, also above market averages.

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Our AI price prediction model suggests that Neumora Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.44%, with price expected at $2.48 by May 20, 2026, within a range of $2.33 to $2.62 3-Month Outlook: Projected rise of 262.66%, reaching $8.45 by August 04, 2026, with a range of $7.05 to $9.33. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 06, 2027, within a range of $0.00 to $0.59.

Key Takeaways

Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) shares are flat 4.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Neumora Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -1.64. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.67, suggesting 529.61% upside. Our AI forecast model points to short-term strength (6.44% over two weeks), a medium-term rise (262.66% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Neumora Therapeutics, Inc. Common Stock (NMRA) stock price?

NMRA's industry and sector of operation?

Who are the executives of NMRA?

No Data

How NMRA did perform over past 52-week?

NMRA's closing price is 281.34% higher than its 52-week low of $0.61 where as its distance from 52-week high of $3.65 is -36.16%.

How many employees does NMRA have?

Number of NMRA employees currently stands at 110.

Link for NMRA official website?

Official Website of NMRA is: https://www.neumoratx.com

How do I contact NMRA?

NMRA could be contacted at phone 857 760 0900 and can also be accessed through its website. NMRA operates from 490 Arsenal Way, Watertown, DE 02472, United States.

How many shares of NMRA are traded daily?

NMRA stock volume for the day was 1.71M shares. The average number of NMRA shares traded daily for last 3 months was 1.43M.

What is the market cap of NMRA currently?

The market value of NMRA currently stands at $425.66M with its latest stock price at $2.33 and 182.69M of its shares outstanding.

Employees	110
Beta	3.12
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

Employees	110
Beta	3.12
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

NMRA Company Profile and Key Details

Neumora Therapeutics Common Stock

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Key Takeaways

Price Forecast & Outlook